Hisamitsu Pharmaceutical Co (TSE:4530) Other Net Income (Loss) : 円-2 Mil (TTM As of Nov. 2023)

View and export this data going back to 1962. Start your Free Trial

What is Hisamitsu Pharmaceutical Co Other Net Income (Loss)?

Hisamitsu Pharmaceutical Co's Other Net Income (Loss) for the three months ended in Nov. 2023 was 円1 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Nov. 2023 was 円-2 Mil.

Hisamitsu Pharmaceutical Co's quarterly Other Net Income (Loss) increased from May. 2023 (円-1 Mil) to Aug. 2023 (円0 Mil) and increased from Aug. 2023 (円0 Mil) to Nov. 2023 (円1 Mil).

Hisamitsu Pharmaceutical Co's annual Other Net Income (Loss) stayed the same from Feb. 2022 (円-1 Mil) to Feb. 2023 (円-1 Mil) but then declined from Feb. 2023 (円-1 Mil) to Feb. 2024 (円-2 Mil).

Hisamitsu Pharmaceutical Co Other Net Income (Loss) Historical Data

The historical data trend for Hisamitsu Pharmaceutical Co's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hisamitsu Pharmaceutical Co Other Net Income (Loss) Chart

Hisamitsu Pharmaceutical Co Annual Data

Trend

Feb15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Feb23

Feb24

Other Net Income (Loss)

Get a 7-Day Free Trial

-1.00

-2.00

Hisamitsu Pharmaceutical Co Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Other Net Income (Loss)	Get a 7-Day Free Trial															-1.00	-1.00	-	1.00	-2.00

Hisamitsu Pharmaceutical Co Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Nov. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-2 Mil.

Hisamitsu Pharmaceutical Co Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Hisamitsu Pharmaceutical Co's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Hisamitsu Pharmaceutical Co (TSE:4530) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hisamitsu Pharmaceutical Co Inc (TSE:4530) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

HPX:Germany

Address

408 Tashiro Daikan-machi, Tosu, Saga, JPN, 841-0017

Website

http://www.hisamitsu.co.jp

Hisamitsu Pharmaceutical Co Inc is a major pharmaceutical products manufacturer in Japan. The company collaborates with its subsidiaries and associates in operating its business across two segments, The Medical and Related Product segment and the Others segment. The Medical segment represents the company's foremost revenue generating operations. It markets drugs under the Salanpas, Salonsip, Lifecella, Mohrus and Keplat brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions and ointments. The Others segment refers to its miscellaneous businesses such as cable television broadcasting, internet connection, packing materials and insurance. Apart from its primary market in Japan, Hisamitsu has a reach across other regions like North America.

Hisamitsu Pharmaceutical Co (TSE:4530) Headlines

No Headlines